{ "meta": { "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.", "terms": "https://open.fda.gov/terms/", "license": "https://open.fda.gov/license/", "last_updated": "2025-09-19", "results": { "skip": 0, "limit": 1, "total": 1 } }, "results": [ { "codes": [ { "uuid": "3affe527-a364-45f3-ae2b-4810cb280dc7", "code": "P10275", "type": "PRIMARY", "url": "http://www.uniprot.org/uniprot/P10275", "code_system": "UNIPROT", "references": [ "6eb6957b-1aa4-444e-b21f-d8718e506dff" ] }, { "uuid": "ffd4ecc1-dd77-4017-a92b-067682f62773", "code": "EJC4C3UYXH", "type": "PRIMARY", "code_system": "FDA UNII" }, { "uuid": "941fcbef-5db7-4342-9e59-464a4a310844", "code": "DTO_00117516", "comments": "Drug Target Ontology|Nuclear hormone receptor|3-ketosteroid receptors|Androgen receptor", "type": "PRIMARY", "url": "http://www.drugtargetontology.org/dto/DTO_00117516", "code_system": "DRUG TARGET ONTOLOGY" } ], "substance_class": "protein", "references": [ { "uuid": "a8398f68-7481-4473-b2cb-d34aaa492267", "citation": "https://en.wikipedia.org/wiki/Dimethandrolone_undecanoate", "doc_type": "WIKI", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE", "NOMEN" ] }, { "uuid": "7a99878c-5fb7-441a-a7d2-d9e6d8e70a07", "citation": "EUR J HEART FAIL. 2017 APR 12. DOI: 10.1002/EJHF.814", "url": "https://www.ncbi.nlm.nih.gov/pubmed/28401618", "doc_type": "JOURNAL ARTICLE", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "181d9bef-9ceb-4d19-bee5-13c60ca8d868", "citation": "UROL ONCOL. 2016 AUG;34(8):348-55. DOI: 10.1016/J.UROLONC.2015.05.025", "url": "https://www.ncbi.nlm.nih.gov/pubmed/26162486", "doc_type": "JOURNAL ARTICLE", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "0fe402ad-4516-410a-b58b-7ae2c5728a78", "citation": "Moilanen, Anu-Maarit, et al. \"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.\" Scientific reports 5 (2015): 12007.", "url": "https://www.nature.com/articles/srep12007", "doc_type": "JA", "public_domain": true }, { "uuid": "960137bb-cb8c-45c0-90b8-7be6ec276790", "citation": "Moilanen, Anu-Maarit, et al. \"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.\" Scientific reports 5 (2015): 12007.", "url": "https://www.nature.com/articles/srep12007", "doc_type": "JA", "public_domain": true }, { "uuid": "3ef0f2c9-766d-43ba-a657-4defefb258fe", "citation": "Moilanen, Anu-Maarit, et al. \"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.\" Scientific reports 5 (2015): 12007.", "url": "https://www.nature.com/articles/srep12007", "doc_type": "JA", "public_domain": true }, { "uuid": "11b93b91-8b76-4c13-bae4-f13ddccd22d7", "citation": "UNIPROT", "doc_type": "UNIPROT", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "6eb6957b-1aa4-444e-b21f-d8718e506dff", "citation": "SRS CODE IMPORT", "doc_type": "SRS", "public_domain": true, "document_date": 1493393933000, "tags": [ "NOMEN" ] }, { "uuid": "abb9c9ce-2641-4f14-93d6-5197a7a19877", "citation": "http://www.selleckchem.com/products/Ostarine.html", "url": "http://www.selleckchem.com/products/Ostarine.html", "doc_type": "BOOK", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "b9f58ac8-6286-42ae-a37c-646b7ef89609", "citation": "http://www.selleckchem.com/Androgen-Receptor.html", "url": "http://www.selleckchem.com/Androgen-Receptor.html", "doc_type": "BOOK", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "8f98084f-a9f1-4372-96d5-a79e3c3b14c9", "citation": "http://www.selleckchem.com/products/arn-509.html", "url": "http://www.selleckchem.com/products/arn-509.html", "doc_type": "BOOK", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "72f934f0-945e-480d-9843-08bc59e77666", "citation": "http://www.selleckchem.com/products/cyproterone-acetate.html", "url": "http://www.selleckchem.com/products/cyproterone-acetate.html", "doc_type": "BOOK", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "ac2a0f1d-4ac2-4f4b-983b-4c953c1c7c48", "citation": "http://www.selleckchem.com/products/fluoxymesterone.html", "url": "http://www.selleckchem.com/products/fluoxymesterone.html", "doc_type": "BOOK", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "ce16afd0-9fa7-49fc-aacc-6f0eed1c4e51", "citation": "SRS import [EJC4C3UYXH]", "url": "http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=EJC4C3UYXH", "doc_type": "SRS", "public_domain": true, "document_date": 1493393933000, "tags": [ "NOMEN" ] }, { "uuid": "1aebf022-acfd-43df-b384-e318fd3bad2c", "citation": "http://www.uniprot.org/uniprot/P10275", "url": "http://www.uniprot.org/uniprot/P10275", "doc_type": "SRS", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE", "AUTO_SELECTED" ] }, { "uuid": "bc75eaee-6295-7fe0-021c-b7ba36f5db83", "citation": "https://en.wikipedia.org/wiki/Androgen_receptor", "doc_type": "WIKI", "public_domain": true }, { "uuid": "23735dfb-db00-4814-acfc-092bd863378b", "citation": "EUR J HEART FAIL. 2017 APR 12. DOI: 10.1002/EJHF.814", "url": "https://www.ncbi.nlm.nih.gov/pubmed/28401618", "doc_type": "JOURNAL ARTICLE", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "d23df9f2-b8f5-47d1-b74a-fcd53130fe00", "citation": "Angus, Lachlan, et al. \"Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving estradiol therapy.\" Endocrine connections 1.aop (2019).", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488394/", "doc_type": "JA", "public_domain": true }, { "uuid": "3094b86a-0e44-4a64-ab92-8287ae817a96", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "bca4dca7-1e38-4957-b7ce-f283106e6c0a", "citation": "https://adisinsight.springer.com/drugs/800046937", "doc_type": "WEB PAGE", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "210df12e-8125-487e-934e-70e741795f7b", "citation": "https://www.prnewswire.com/news-releases/arvinas-presents-new-preclinical-data-on-oral-androgen-receptor-protac-arv-110-at-asco-2018-genitourinary-cancers-symposium-300596260.html", "url": "https://www.prnewswire.com/news-releases/arvinas-presents-new-preclinical-data-on-oral-androgen-receptor-protac-arv-110-at-asco-2018-genitourinary-cancers-symposium-300596260.html", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "ad6d6d94-f774-4b2d-83d5-5b7f3c148c0f", "citation": "WIKIPEDIA", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "9ab81baa-57fa-4231-9294-2bf3ed1066de", "citation": "Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998–2021)European Journal of Medicinal Chemistry Available online 12 January 2022, 114119", "url": "https://www.sciencedirect.com/science/article/pii/S0223523422000216", "doc_type": "JA", "public_domain": true }, { "uuid": "f677e291-7499-4805-9a11-ead3be032af1", "citation": "Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998–2021)European Journal of Medicinal Chemistry Available online 12 January 2022, 114119", "url": "https://www.sciencedirect.com/science/article/pii/S0223523422000216", "doc_type": "JA", "public_domain": true }, { "uuid": "53f863a0-6aaf-4102-a843-56d1d273c9a0", "citation": "Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998–2021)European Journal of Medicinal Chemistry Available online 12 January 2022, 114119", "url": "https://www.sciencedirect.com/science/article/pii/S0223523422000216", "doc_type": "JA", "public_domain": true }, { "uuid": "89ed3db0-c479-4e17-8dd2-623893093439", "citation": "Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998–2021)European Journal of Medicinal Chemistry Available online 12 January 2022, 114119", "url": "https://www.sciencedirect.com/science/article/pii/S0223523422000216", "doc_type": "JA", "public_domain": true }, { "uuid": "a11bb419-f596-4ff3-aa52-1189d4cb4f1f", "citation": "http://onlinelibrary.wiley.com/doi/10.1002/rcm.7189/full", "url": "http://onlinelibrary.wiley.com/doi/10.1002/rcm.7189/full", "doc_type": "JOURNAL ARTICLE", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "d7ae7932-7ecd-4564-a08e-520ab07586a9", "citation": "http://onlinelibrary.wiley.com/doi/10.1002/rcm.7189/full", "url": "http://onlinelibrary.wiley.com/doi/10.1002/rcm.7189/full", "doc_type": "JOURNAL ARTICLE", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "3784ffcc-7620-4dd9-814c-831facb294d2", "citation": "Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998–2021)European Journal of Medicinal Chemistry Available online 12 January 2022, 114119", "url": "https://www.sciencedirect.com/science/article/pii/S0223523422000216", "doc_type": "JA", "public_domain": true }, { "uuid": "50d08dea-b33d-46a5-9e7a-e5021d83088b", "citation": "Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998–2021)European Journal of Medicinal Chemistry Available online 12 January 2022, 114119", "url": "https://www.sciencedirect.com/science/article/pii/S0223523422000216", "doc_type": "JA", "public_domain": true }, { "uuid": "e6f90340-65b8-4e5e-9ecb-188c6cc89fef", "citation": "Fonseca, Guilherme Wesley Peixoto Da, et al. \"Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials.\" Expert Opinion on Investigational Drugs 29.8 (2020): 881-891.", "url": "https://reader.elsevier.com/reader/sd/pii/S0223523422000216?token=659242A0DB23FAC6B0E0F08E5F11B61375F05845D7E45D57BD46F7ECA86ED709CBF81DB15B02CF0AD8D18504BD7239C5&originRegion=us-east-1&originCreation=20220116233043", "doc_type": "JA", "public_domain": true }, { "uuid": "a26f73a1-92d6-45ab-abb2-a3440eecd5c8", "citation": "https://en.wikipedia.org/wiki/Methyltestosterone", "url": "https://en.wikipedia.org/wiki/Methyltestosterone", "doc_type": "WIKI", "public_domain": true }, { "uuid": "d60de41f-cf93-456c-a930-6a063a55b6d3", "citation": "Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998–2021)European Journal of Medicinal Chemistry Available online 12 January 2022, 114119", "url": "https://www.sciencedirect.com/science/article/pii/S0223523422000216", "doc_type": "JA", "public_domain": true }, { "uuid": "de44bd74-56fc-45fb-9ae3-d3d6360b3907", "citation": "MARTINDALE", "doc_type": "MARTINDALE", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "39f838c0-a01e-4712-9068-cc8d53490b1c", "citation": "https://en.wikipedia.org/wiki/1-Androsterone", "doc_type": "WIKI", "public_domain": true }, { "uuid": "8bb6069a-5a61-4c4e-beca-c96b1ae3e9e8", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "5563bf58-ed90-49b2-8d9c-e9c2728d82aa", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "66122144-36ba-4503-8ff5-93cfb3eab4ee", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "d202d796-6f7c-4e64-a3c4-269e0327ddff", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "326c1dd1-f9e7-4716-92c1-15bbe264de1c", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "d1ae6ebb-6cd4-468a-850a-50b3f770e4f3", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "e04030d4-983a-40bf-9d4f-d3ad9dd30014", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "81004fb5-5584-4fb6-8549-350f174760df", "citation": "WIKI", "url": "https://en.wikipedia.org/wiki/5%CE%B1-Dihydronorethandrolone", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "f5b90096-42c0-4784-a399-bc9ae26f20a8", "citation": "https://adisinsight.springer.com/drugs/800046937", "doc_type": "WEB PAGE", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "43afb71b-9b78-49d2-adf3-e764566d0519", "citation": "Nieschlag, Eberhard, Narender Kumar, and Régine Sitruk-Ware. \"7α-methyl-19-nortestosterone (MENTR): the population council's contribution to research on male contraception and treatment of hypogonadism.\" Contraception 87.3 (2013): 288-295.", "url": "https://www.sciencedirect.com/science/article/pii/S0010782412008025", "doc_type": "JA", "public_domain": true }, { "uuid": "2e36cd1e-9426-4354-af12-4f8a09e0b44b", "citation": "Obst JK, Wang J, Jian K, Williams DE, Tien AH, Mawji N, Tam T, Yang YC, Andersen RJ, Chi KN, Montgomery B, Sadar MD. Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. ACS Pharmacol Transl Sci. 2019 Sep 26;2(6):453-467. doi: 10.1021/acsptsci.9b00065. PMID: 32259077; PMCID: PMC7088963.", "url": "https://pubmed.ncbi.nlm.nih.gov/32259077/", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "8871c13d-ba5c-4a12-876f-eb6735a29268", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "a695b197-fa00-4ea2-8033-af136ae3b081", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "a8d2daec-f06e-485f-937d-e705bd2a3ae9", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "76873134-3dd6-42d0-a08d-6a9313de2ac3", "citation": "https://www.guidetoimmunopharmacology.org/GRAC/LigandDisplayForward?tab=similarity&ligandId=10182", "url": "https://www.guidetoimmunopharmacology.org/GRAC/LigandDisplayForward?tab=similarity&ligandId=10182", "doc_type": "IUPHAR", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "4f5b450b-3e85-46e9-9e8f-b58e4b465080", "citation": "NCIT", "doc_type": "NCI THESAURUS", "public_domain": true }, { "uuid": "3a21725e-bd3d-47b6-910b-0f11e893d3cb", "citation": "Beattie, Bradley J., et al. \"Pharmacokinetic assessment of the uptake of 16β-18F-fluoro-5α-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.\" Journal of nuclear medicine 51.2 (2010): 183-192.", "url": "https://jnm.snmjournals.org/content/51/2/183.short", "doc_type": "JA", "public_domain": true }, { "uuid": "d930739b-939b-4048-99df-0eea1aab1a02", "citation": "WIK", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "7670a421-f7a4-416c-a768-f678ced55be7", "citation": "WIKI", "doc_type": "WIKI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "c99be1dc-b781-4097-b0da-855925e70277", "citation": "Beer, Carolin, and Annekathrin M. Keiler. \"Androgenic properties of the dietary supplement 5α-hydroxy-laxogenin.\" Archives of Toxicology 96.7 (2022): 2139-2142.", "url": "https://link.springer.com/content/pdf/10.1007/s00204-022-03283-5.pdf", "doc_type": "JA", "public_domain": true }, { "uuid": "f05b76ee-23fa-4248-80f4-f4e7fc387f53", "citation": "MARTINDALE", "doc_type": "MARTINDALE", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "35f267c5-ff00-46f8-8bff-168fecbe1bd6", "citation": "https://en.wikipedia.org/wiki/1-Androsterone", "doc_type": "WIKI", "public_domain": true }, { "uuid": "2fdc4026-fc90-419e-bb4d-4e978916af3e", "citation": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/933", "url": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/933", "doc_type": "ASSAY REFERENCE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "68a64a85-b8b8-4c5f-a74a-d9dc2347d2bd", "citation": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/933", "url": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/933", "doc_type": "ASSAY REFERENCE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "8f29ac37-08f0-4f97-aeb7-d1a373c93501", "citation": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/933", "url": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/933", "doc_type": "ASSAY REFERENCE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "ac76683f-2dd2-4266-8b9c-06f991d804a3", "citation": "https://adisinsight.springer.com/drugs/800018266", "url": "https://adisinsight.springer.com/drugs/800018266", "doc_type": "WEB PAGE", "public_domain": true }, { "uuid": "d4f64027-8331-4453-8137-c35ec2a9da79", "citation": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/933", "url": "https://www.eurofinsdiscovery.com/catalogmanagement/viewItem/933", "doc_type": "ASSAY REFERENCE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "1b38fa3e-1f9c-4cea-8eff-6779919abbe2", "citation": "Oksala, Riikka, et al. \"Discovery and development of ODM-204: a novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.\" The Journal of steroid biochemistry and molecular biology 192 (2019): 105115.", "url": "https://www.sciencedirect.com/science/article/pii/S0960076018300785", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "875b7710-87f4-47a8-9e88-432992826990", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] } ], "definition_type": "PRIMARY", "definition_level": "COMPLETE", "uuid": "53389a82-61c4-4a11-84b6-1be471e934b3", "version": "105", "unii": "EJC4C3UYXH", "relationships": [ { "uuid": "5f8bcc1b-77ca-4c39-9b64-8ab8a8c9ab1a", "amount": { "uuid": "86cb67ca-c91c-4867-babb-5db239f1ca38" }, "type": "AGONIST->TARGET", "related_substance": { "uuid": "6edf1a06-a230-402a-978e-2f90a3e2feea", "refuuid": "641ae037-be35-4143-ad7a-ecfd6bac5291", "name": "GSK-2881078", "unii": "47M5ZXU844", "linking_id": "47M5ZXU844", "ref_pname": "GSK-2881078" } }, { "uuid": "a44f44b3-1d6e-413a-94cc-baa10c74b65b", "amount": { "uuid": "53fc7921-018f-48c5-94f2-2b6850d7216d", "type": "RELATIONSHIP_AMOUNT", "average": 3.8, "units": "NANOMOLAR" }, "comments": "MK-2866 (GTx-024) is a selective androgen receptor modulator (SARM) with Ki of 3.8 nM, and is tissue-selective for anabolic organs. Phase 3.", "qualification": "IC50", "type": "AGONIST->TARGET", "interaction_type": "ANTAGONIST", "references": [ "abb9c9ce-2641-4f14-93d6-5197a7a19877" ], "related_substance": { "uuid": "888fb7af-0eb1-4022-b842-2821449ffae0", "refuuid": "63c6b1ef-7508-4c2b-a447-99d28f58f959", "name": "ENOBOSARM", "unii": "O3571H3R8N", "linking_id": "O3571H3R8N", "ref_pname": "ENOBOSARM", "substance_class": "reference" } }, { "uuid": "56569949-d408-4dc5-b43c-48aa8c5bbfb0", "amount": { "uuid": "e646dde7-4b82-425a-94c2-80fa64a9eec3", "type": "RELATIONSHIP_AMOUNT", "average": 36, "units": "NANOMOLAR" }, "comments": "an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells.", "qualification": "IC50", "type": "INHIBITOR->TARGET", "interaction_type": "ANTAGONIST", "references": [ "b9f58ac8-6286-42ae-a37c-646b7ef89609" ], "related_substance": { "uuid": "1f2c6786-a997-4ce2-a8fe-e283fb955bc4", "refuuid": "7298691a-2e95-4ce8-b3dd-faf2be60a5a2", "name": "ENZALUTAMIDE", "unii": "93T0T9GKNU", "linking_id": "93T0T9GKNU", "ref_pname": "ENZALUTAMIDE", "substance_class": "reference" } }, { "uuid": "872a2234-a575-4d23-8d4b-927bac34fef7", "amount": { "uuid": "0accb541-3434-4d47-b8ba-4cc5df41e5ed", "type": "RELATIONSHIP_AMOUNT", "average": 0.16, "units": "MICROMOLAR" }, "comments": "Bicalutamide\n\nBicalutamide is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line", "qualification": "IC50", "type": "INHIBITOR->TARGET", "interaction_type": "ANTAGONIST", "references": [ "b9f58ac8-6286-42ae-a37c-646b7ef89609" ], "related_substance": { "uuid": "a0a6d4d2-75e2-4592-bb56-a66ce75538ca", "refuuid": "8f5c0a0d-71ce-49ae-92eb-b6685e0e0671", "name": "BICALUTAMIDE", "unii": "A0Z3NAU9DP", "linking_id": "A0Z3NAU9DP", "ref_pname": "BICALUTAMIDE", "substance_class": "reference" } }, { "uuid": "a955d562-655e-4e8e-bdf1-ffbfcd3348fa", "amount": { "uuid": "1abc0eff-65f0-43f4-81ac-e93ae739e28f", "type": "RELATIONSHIP_AMOUNT", "average": 16, "units": "NANOMOLAR" }, "comments": "ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM in a cell-free assay, useful for prostate cancer treatment. Phase 3", "qualification": "IC50", "type": "INHIBITOR->TARGET", "interaction_type": "ANTAGONIST", "references": [ "8f98084f-a9f1-4372-96d5-a79e3c3b14c9" ], "related_substance": { "uuid": "36885810-9423-4b04-8ab0-2d044035258b", "refuuid": "2ab1bf10-cfd8-4c86-a293-5580a9006455", "name": "Apalutamide", "unii": "4T36H88UA7", "linking_id": "4T36H88UA7", "ref_pname": "Apalutamide", "substance_class": "reference" } }, { "uuid": "ca8453ee-52f2-43a9-a372-2ea3c740c009", "amount": { "uuid": "7ec4d113-56ad-40b2-9822-43e0b9c76133", "type": "RELATIONSHIP_AMOUNT", "average": 384, "units": "NANOMOLAR" }, "comments": "Galeterone is a selective CYP17 inhibitor and androgen receptor (AR) antagonist with IC50 of 300 nM and 384 nM, respectively, and is a potent inhibitor of human prostate tumor growth. Phase 2.", "qualification": "IC50", "type": "AGONIST->TARGET", "interaction_type": "ANTAGONIST", "references": [ "b9f58ac8-6286-42ae-a37c-646b7ef89609" ], "related_substance": { "uuid": "eed70fd0-3cf6-4c36-a356-988d96f88a0f", "refuuid": "8597baeb-12bb-4c3a-8284-2c16396aeb60", "name": "GALETERONE", "unii": "WA33E149SW", "linking_id": "WA33E149SW", "ref_pname": "GALETERONE", "substance_class": "reference" } }, { "uuid": "9cc3d48d-cc8d-4834-ba89-c0f9a0d83bc6", "amount": { "uuid": "b6d21752-f983-4383-bc86-0a1c7bc454c2", "type": "RELATIONSHIP_AMOUNT", "average": 55, "units": "NANOMOLAR" }, "comments": "Flutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor with Ki values of 55 nM, and primarily used to treat prostate cancer", "qualification": "IC50", "type": "INHIBITOR->TARGET", "interaction_type": "ANTAGONIST", "references": [ "b9f58ac8-6286-42ae-a37c-646b7ef89609" ], "related_substance": { "uuid": "d5a34b3b-6e8f-4095-bc60-e49f20d9f6e8", "refuuid": "ceb90449-01d7-485e-b6b3-ee173f370818", "name": "FLUTAMIDE", "unii": "76W6J0943E", "linking_id": "76W6J0943E", "ref_pname": "FLUTAMIDE", "substance_class": "reference" } }, { "uuid": "45722e58-a931-4d20-8993-206a6250e586", "amount": { "uuid": "3353af43-ded8-414a-a361-5f06328dca4d", "type": "RELATIONSHIP_AMOUNT", "average": 7.1, "units": "NANOMOLAR" }, "comments": "Cyproterone acetate is an androgen receptor (AR) antagonist with IC50 of 7.1 nM, as well as a weak progesterone receptor agonist with weak pro-gestational and glucocorticoid activity", "qualification": "IC50", "type": "AGONIST->TARGET", "interaction_type": "ANTAGONIST", "references": [ "b9f58ac8-6286-42ae-a37c-646b7ef89609" ], "related_substance": { "uuid": "bd29af81-0b59-4e9e-b109-994ad7f9fedc", "refuuid": "4713e2c6-1dfb-45a2-acf6-e599d1430ef9", "name": "CYPROTERONE", "unii": "E61Q31EK2F", "linking_id": "E61Q31EK2F", "ref_pname": "CYPROTERONE", "substance_class": "reference" } }, { "uuid": "5714df1b-4e05-4c9c-a098-0c79c14bad51", "amount": { "uuid": "cb29e307-e82f-4d0b-b3e8-b4480ca5719a", "type": "RELATIONSHIP_AMOUNT", "average": 4, "units": "NANOMOLAR" }, "comments": "Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs. Phase 3", "qualification": "IC50", "type": "AGONIST->TARGET", "interaction_type": "ANTAGONIST", "references": [ "b9f58ac8-6286-42ae-a37c-646b7ef89609" ], "related_substance": { "uuid": "44b2ded7-312f-46e3-984e-b673880f1698", "refuuid": "52f272d7-c8a1-440a-be06-449464a83456", "name": "ANDARINE", "unii": "7UT2HAH49H", "linking_id": "7UT2HAH49H", "ref_pname": "ANDARINE", "substance_class": "reference" } }, { "uuid": "c8535a37-7337-44ea-95c9-f9a23b0a913e", "amount": { "uuid": "07b98215-f9bd-4964-b21d-1856d83048b1", "type": "RELATIONSHIP_AMOUNT", "average": 100, "units": "NANOMOLAR" }, "comments": "Dehydroepiandrosterone is an important endogenous steroid hormone, which is an androgen receptor antagonist and an estrogen receptor agonist", "qualification": "IC50", "type": "AGONIST->TARGET", "interaction_type": "ANTAGONIST", "references": [ "b9f58ac8-6286-42ae-a37c-646b7ef89609" ], "related_substance": { "uuid": "78d74270-e3cf-41a9-8612-3c1a402a4ea4", "refuuid": "b331d3c4-1d2a-4868-ae54-33988b31c01f", "name": "PRASTERONE", "unii": "459AG36T1B", "linking_id": "459AG36T1B", "ref_pname": "PRASTERONE", "substance_class": "reference" } }, { "uuid": "8224d156-90c0-44ab-9c64-9865e2b6c7e5", "amount": { "uuid": "089fc80a-0618-45cb-aa7a-989a7263eddf" }, "qualification": "IC50", "type": "PARTIAL ANTAGONIST->TARGET", "interaction_type": "BINDING", "references": [ "23735dfb-db00-4814-acfc-092bd863378b", "d23df9f2-b8f5-47d1-b74a-fcd53130fe00" ], "related_substance": { "uuid": "a8112ec0-55f1-4b39-80b9-68f086a3d65d", "refuuid": "61407b8f-da7a-4899-bbb6-94b1b6752859", "name": "SPIRONOLACTONE", "unii": "27O7W4T232", "linking_id": "27O7W4T232", "ref_pname": "SPIRONOLACTONE", "substance_class": "reference" } }, { "uuid": "a3525351-05b8-4a00-a1fc-45ce9affd929", "amount": { "uuid": "40b9bdfb-8eb8-481d-b03e-bcdbe35632e0", "average": 11, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "interaction_type": "BINDING", "references": [ "181d9bef-9ceb-4d19-bee5-13c60ca8d868", "0fe402ad-4516-410a-b58b-7ae2c5728a78" ], "related_substance": { "uuid": "0861e962-581f-402c-ac8b-c4f205671e4e", "refuuid": "753e991b-b554-442a-ad28-84815869b380", "name": "DAROLUTAMIDE", "unii": "X05U0N2RCO", "linking_id": "X05U0N2RCO", "ref_pname": "DAROLUTAMIDE", "substance_class": "reference" } }, { "uuid": "1bed0b77-18b9-4374-8757-dd587d5d770e", "amount": { "uuid": "25e88366-df35-4e1a-8ca5-aa16b76c0c94", "type": "RELATIONSHIP_AMOUNT", "average": 7.1, "units": "NANOMOLAR" }, "comments": "Cyproterone acetate is an androgen receptor (AR) antagonist with IC50 of 7.1 nM, as well as a weak progesterone receptor agonist with weak pro-gestational and glucocorticoid activity.", "qualification": "IC50", "type": "AGONIST->TARGET", "interaction_type": "ANTAGONIST", "references": [ "72f934f0-945e-480d-9843-08bc59e77666" ], "related_substance": { "uuid": "00db7907-c0d2-4657-8044-50df61ff0073", "refuuid": "a3bdbd07-dfa1-48c7-bd38-8fe8814edbd0", "name": "Cyproterone Acetate", "unii": "4KM2BN5JHF", "linking_id": "4KM2BN5JHF", "ref_pname": "Cyproterone Acetate", "substance_class": "reference" } }, { "uuid": "061eb069-b356-4c40-bdd6-264f50e80970", "comments": "Fluoxymesterone is an Androgen. The mechanism of action of fluoxymesterone is as an Androgen Receptor Agonist", "qualification": "IC50", "type": "AGONIST->TARGET", "interaction_type": "ANTAGONIST", "references": [ "ac2a0f1d-4ac2-4f4b-983b-4c953c1c7c48" ], "related_substance": { "uuid": "11ac0046-efc5-426d-8963-f24bb0287bf0", "refuuid": "18baa5c4-d627-489c-801c-c2aee94fa020", "name": "FLUOXYMESTERONE", "unii": "9JU12S4YFY", "linking_id": "9JU12S4YFY", "ref_pname": "FLUOXYMESTERONE", "substance_class": "reference" } }, { "uuid": "8b5c31d5-b412-4ae4-bb68-3e9139661f31", "amount": { "uuid": "c19ee260-ec13-4e98-b1b8-a84bfbb47e66" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "e873a37d-ea73-4754-a9d4-bd26cadbfd52", "refuuid": "9fee9cab-da45-4cd4-b8ae-e6e5e15e2118", "name": "TRC-253", "unii": "GNG9GQ9Y27", "linking_id": "GNG9GQ9Y27", "ref_pname": "TRC-253" } }, { "uuid": "5a562c65-be8e-4592-8098-eeab29d015ad", "amount": { "uuid": "10539ee1-54a6-46ae-b2eb-4186c0f670b6" }, "type": "AGONIST->TARGET", "related_substance": { "uuid": "c1998cfc-95b8-498c-b330-762dfc8d5356", "refuuid": "a3b3fa6d-251e-4196-bf01-134140f54245", "name": "ANDROSTANOLONE", "unii": "08J2K08A3Y", "linking_id": "08J2K08A3Y", "ref_pname": "ANDROSTANOLONE", "substance_class": "reference" } }, { "uuid": "9a945a79-e8ce-48d2-909d-fc0f2e014b32", "type": "AGONIST->TARGET", "related_substance": { "uuid": "dbb15d1d-36cd-4ddb-bb34-b46f2512e577", "refuuid": "7298691a-2e95-4ce8-b3dd-faf2be60a5a2", "name": "ENZALUTAMIDE", "unii": "93T0T9GKNU", "linking_id": "93T0T9GKNU", "ref_pname": "ENZALUTAMIDE" } }, { "uuid": "bef65169-7892-489f-8829-0c622b5c759e", "type": "AGONIST->TARGET", "related_substance": { "uuid": "91424e23-6b00-41d0-95dd-322319a731cf", "refuuid": "8f5c0a0d-71ce-49ae-92eb-b6685e0e0671", "name": "BICALUTAMIDE", "unii": "A0Z3NAU9DP", "linking_id": "A0Z3NAU9DP", "ref_pname": "BICALUTAMIDE" } }, { "uuid": "362c9290-708e-43cc-adae-86efbe10c88b", "amount": { "uuid": "1d2bd21c-5ef5-458f-be34-fa3ea0446883" }, "type": "AGONIST->TARGET", "references": [ "d7ae7932-7ecd-4564-a08e-520ab07586a9", "3784ffcc-7620-4dd9-814c-831facb294d2" ], "related_substance": { "uuid": "a281f1c3-0b28-45fb-85a4-daca88ae80d9", "refuuid": "cb6843af-e79e-494a-8a68-604738dd18b3", "name": "VK-5211", "unii": "1EJT54415A", "linking_id": "1EJT54415A", "ref_pname": "VK-5211" } }, { "uuid": "139fa2cc-4d82-485d-bbb0-c3ffed396b4e", "amount": { "uuid": "04ba6b55-caa6-4afe-867d-f085357b9a50" }, "type": "AGONIST->TARGET", "references": [ "9ab81baa-57fa-4231-9294-2bf3ed1066de" ], "related_substance": { "uuid": "837b9b49-c6e0-4301-92f7-b17f210dc305", "refuuid": "0779f7bb-8305-4725-b488-b233178cf96e", "name": "GLPG-0492", "unii": "8O59X1ACZT", "linking_id": "8O59X1ACZT", "ref_pname": "GLPG-0492", "substance_class": "reference" } }, { "uuid": "8ecd86de-7d06-4282-a0e9-4eb3c227b11d", "amount": { "uuid": "6fdc645f-a794-4830-bb59-b2b36841586c" }, "type": "AGONIST->TARGET", "references": [ "53f863a0-6aaf-4102-a843-56d1d273c9a0" ], "related_substance": { "uuid": "3bc45420-8ac0-4229-a94b-b6c089e5712a", "refuuid": "b503ac56-3ca3-4aa0-895f-69526214e288", "name": "GSK-971086", "unii": "8TFL50092H", "linking_id": "8TFL50092H", "ref_pname": "GSK-971086", "substance_class": "reference" } }, { "uuid": "d90cc6ed-c672-4cfa-8922-fea6b15c2793", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "f0ed600f-d189-4597-8b37-5a771b08f52a", "refuuid": "c8eaa6b8-72f9-400e-92cb-d4e2c648957c", "name": "N-Desmethylapalutamide", "unii": "13RV85F63R", "linking_id": "13RV85F63R", "ref_pname": "N-Desmethylapalutamide" } }, { "uuid": "9f04454e-5570-4521-828d-15a8823d306d", "type": "AGONIST->TARGET", "related_substance": { "uuid": "5328f958-e2ec-415a-b5a6-e54d0da5b0ae", "refuuid": "9494b30f-f4b5-4725-b15c-152d1152e405", "name": "DANAZOL", "unii": "N29QWW3BUO", "linking_id": "N29QWW3BUO", "ref_pname": "DANAZOL" } }, { "uuid": "da647adf-9d05-4467-a548-4ae75177a44e", "amount": { "uuid": "67440d8a-945b-4dd3-8aa9-a6319fc1b5a4", "average": 55, "units": "NANOMOLAR" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "af59984e-3e45-4bbd-9716-099d899dd516", "refuuid": "d03e4594-27bc-47ec-a7ee-75a45aa9cb63", "name": "Faznolutamide", "unii": "77SI04TT7L", "linking_id": "77SI04TT7L", "ref_pname": "Faznolutamide" } }, { "uuid": "f09627bf-a640-4640-9d52-daab4a58f194", "type": "INHIBITOR OF EXPRESSION->TARGET", "related_substance": { "uuid": "fe64e7d0-0049-4c6c-80cd-93dcb7a24377", "refuuid": "8aa8db4b-69ed-477c-8362-932439fb1a1f", "name": "AZD-5312 FREE ACID", "unii": "9FWK7K3143", "linking_id": "9FWK7K3143", "ref_pname": "AZD-5312 FREE ACID" } }, { "uuid": "42fcfce5-8bf9-4557-a86a-6e25f6082bd9", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "dcaf94de-fd77-43b3-a5b5-fadc922bbac4", "refuuid": "cfc8e5b6-38f6-4f36-a13b-3e50284e5dc6", "name": "AZD-5312", "unii": "3S31QX1Q6J", "linking_id": "3S31QX1Q6J", "ref_pname": "AZD-5312" } }, { "uuid": "86ebcd1b-c750-489f-ac2e-0d746a4b12f0", "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "38c14292-9356-42df-9d0e-58864a37d8fe", "refuuid": "2c59390a-7a7a-4709-8134-f9f62cd13824", "name": "REZVILUTAMIDE", "unii": "70FJN2AW22", "linking_id": "70FJN2AW22", "ref_pname": "REZVILUTAMIDE" } }, { "uuid": "c789126a-44a4-49a9-bb86-9f608410d3f4", "amount": { "uuid": "063dffe0-54e8-4fa5-8d1b-cfb9ce1bdd6a" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "2bb62bae-3de0-4ad7-b644-7cf9a0fece23", "refuuid": "276352b8-5545-46f5-852a-3b656e5f931c", "name": "Gumelutamide", "unii": "B7CL5GXS2R", "linking_id": "B7CL5GXS2R", "ref_pname": "Gumelutamide" } }, { "uuid": "52eccd46-273d-4b48-8eb1-53ca50fdff11", "amount": { "uuid": "e110b2b7-374b-44ad-84d4-8dc6d46f1d44" }, "type": "INHIBITOR->TARGET", "references": [ "f5b90096-42c0-4784-a399-bc9ae26f20a8" ], "related_substance": { "uuid": "da44b5cb-2893-4bf1-a941-35badc60a7a8", "refuuid": "de653c11-fd66-4790-974c-d4c3faef6bbf", "name": "BERDAZIMER SODIUM", "unii": "ORT9SID4QY", "linking_id": "ORT9SID4QY", "ref_pname": "BERDAZIMER SODIUM" } }, { "uuid": "9fc46a2d-e8a8-4da9-bb7e-4c24f189e855", "amount": { "uuid": "7be37452-3c1c-4f67-9c90-f093eda48382", "average": 8, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "3ef0f2c9-766d-43ba-a657-4defefb258fe" ], "related_substance": { "uuid": "a46202f1-9003-4ff3-a43e-6925d20192d7", "refuuid": "9368cae0-4e07-4891-95e9-1355a3391514", "name": "KETO-DAROLUTAMIDE", "unii": "9EPS75QMTL", "linking_id": "9EPS75QMTL", "ref_pname": "KETO-DAROLUTAMIDE" } }, { "uuid": "eeb32f37-2f03-486e-96c4-7f3d76944334", "amount": { "uuid": "2d075135-eac4-4b7f-a93a-d47ad22e5d88" }, "type": "INHIBITOR->TARGET", "references": [ "875b7710-87f4-47a8-9e88-432992826990" ], "related_substance": { "uuid": "f0bfb955-ba37-4a90-99f2-6c2b3fcfbb18", "refuuid": "b0eb82c4-1a27-4915-b1c1-6e4d1ab9536e", "name": "Clascoterone", "unii": "XN7MM8XG2M", "linking_id": "XN7MM8XG2M", "ref_pname": "Clascoterone" } }, { "uuid": "774b4ce5-5dff-44da-bf47-9567380e8ea6", "type": "AGONIST->TARGET", "references": [ "a8398f68-7481-4473-b2cb-d34aaa492267" ], "related_substance": { "uuid": "14ac57a2-125a-4aec-98f0-aeb31a9bcb80", "refuuid": "263eb2c5-3db2-443b-8dd6-02db349dd157", "name": "DIMETHANDROLONE UNDECANOATE", "unii": "VMT7Z23GLM", "linking_id": "VMT7Z23GLM", "ref_pname": "DIMETHANDROLONE UNDECANOATE" } }, { "uuid": "c8d93541-45ff-48c1-bea1-898c5cbfe1e8", "type": "AGONIST->TARGET", "references": [ "ad6d6d94-f774-4b2d-83d5-5b7f3c148c0f" ], "related_substance": { "uuid": "1faada65-22ec-4a42-8b8c-e8170527a8c5", "refuuid": "3c1f26b5-8c7c-4478-88cb-93ed17a04b67", "name": "DIMETHYLTRIENOLONE", "unii": "8GP0J5637H", "linking_id": "8GP0J5637H", "ref_pname": "DIMETHYLTRIENOLONE" } }, { "uuid": "83f1448a-37fe-40fb-b096-b31d3e9aba56", "amount": { "uuid": "ead76a0c-3143-4502-8d1e-3593e0a02d50" }, "type": "AGONIST->TARGET", "references": [ "50d08dea-b33d-46a5-9e7a-e5021d83088b" ], "related_substance": { "uuid": "893c6d91-f6bf-46cb-b7ff-54e9a0f817c6", "refuuid": "557a9d65-3c72-4db8-be95-1cc44c172e27", "name": "OPK-88004", "unii": "XKW9MYF94Y", "linking_id": "XKW9MYF94Y", "ref_pname": "OPK-88004", "substance_class": "reference" } }, { "uuid": "80ed1fc0-8e41-4752-af26-b0561c9a56c7", "amount": { "uuid": "8e5ff4cc-8eae-4130-a13f-2b92b47e051b" }, "type": "INHIBITOR->TARGET", "interaction_type": "ANTAGONIST", "references": [ "a695b197-fa00-4ea2-8033-af136ae3b081" ], "related_substance": { "uuid": "c6673b98-be4b-4d7a-9c7b-8100134d3e42", "refuuid": "83836da0-c0a4-43df-8239-05e98ec7569e", "name": "EPI-001", "unii": "A9PRH4DC8H", "linking_id": "A9PRH4DC8H", "ref_pname": "EPI-001" } }, { "uuid": "5e1b56d4-3f6d-419c-b4ed-230d36826457", "amount": { "uuid": "b0138d27-6366-41eb-a761-e2c75804afc7" }, "type": "MODULATOR->TARGET", "references": [ "8871c13d-ba5c-4a12-876f-eb6735a29268" ], "related_substance": { "uuid": "7a7b147c-d942-4c38-b457-526ec055caf6", "refuuid": "c8fb22f1-5682-4bb1-a180-317f631ff10c", "name": "LG-121071", "unii": "242F29CP76", "linking_id": "242F29CP76", "ref_pname": "LG-121071" } }, { "uuid": "879fdde1-4097-48af-9238-887d50bd6c4c", "amount": { "uuid": "4729b993-96b9-410a-a779-0cc94cae4e23" }, "type": "AGONIST->TARGET", "related_substance": { "uuid": "ee426e9f-5da0-4614-9f61-3ebb7dbebef1", "refuuid": "bf87f882-8d09-4ab2-a462-2f66b197ab16", "name": "PF-06260414", "unii": "3I487UHH95", "linking_id": "3I487UHH95", "ref_pname": "PF-06260414", "substance_class": "reference" } }, { "uuid": "99215b36-851e-4cda-8b5d-41ad21a56db0", "amount": { "uuid": "9a9af53d-7f0a-411a-a169-1e62135f8426" }, "type": "AGONIST->TARGET", "references": [ "d60de41f-cf93-456c-a930-6a063a55b6d3" ], "related_substance": { "uuid": "41ddb106-7a4d-4fb4-9e7d-b1f089a21bc7", "refuuid": "602c9749-29e7-4d78-a515-7656812f6335", "name": "MK-3984", "unii": "NDR4H1Q159", "linking_id": "NDR4H1Q159", "ref_pname": "MK-3984", "substance_class": "reference" } }, { "uuid": "e7358d4b-ae93-46af-9a6f-b9fc5f9b8efa", "amount": { "uuid": "e8c16324-a499-4686-a934-9c345592d71f" }, "type": "AGONIST->TARGET", "references": [ "a26f73a1-92d6-45ab-abb2-a3440eecd5c8" ], "related_substance": { "uuid": "b3ec1f5c-fca7-4c75-b8d5-09378461f861", "refuuid": "2edc26bd-ec01-4dc6-b592-bf9bac016048", "name": "METHYLTESTOSTERONE", "unii": "V9EFU16ZIF", "linking_id": "V9EFU16ZIF", "ref_pname": "METHYLTESTOSTERONE", "substance_class": "reference" } }, { "uuid": "3fafd18e-b45f-488e-a9bd-23940c03c37b", "amount": { "uuid": "3a216c7e-a15a-4f9e-99bf-0f5e9cd601fa" }, "type": "AGONIST->TARGET", "related_substance": { "uuid": "08afd941-dc89-4737-9d11-09e5c7241ad2", "refuuid": "7a24ab9f-ecd9-4797-bd9c-31b3c3ca3315", "name": "MESTANOLONE", "unii": "S712YZ168E", "linking_id": "S712YZ168E", "ref_pname": "MESTANOLONE", "substance_class": "reference" } }, { "uuid": "1a6d828e-3055-4b6e-b65e-0192483ca0f7", "amount": { "uuid": "4aac2e37-acf5-4656-81a9-e1e4334ad48a" }, "type": "INHIBITOR->TARGET", "interaction_type": "ANTAGONIST", "references": [ "a8d2daec-f06e-485f-937d-e705bd2a3ae9" ], "related_substance": { "uuid": "68eb4fcf-46b0-434f-84fe-2b30e59e3b0f", "refuuid": "96e49d04-2caf-43be-8b07-9d1c115ad2f6", "name": "LG-120907", "unii": "V4UZ8R6BCK", "linking_id": "V4UZ8R6BCK", "ref_pname": "LG-120907" } }, { "uuid": "8b96d847-7fd5-4538-9bf4-14662ed8637f", "amount": { "uuid": "888a045f-09ef-4658-a6ea-3691ec7383da" }, "type": "AGONIST->TARGET", "references": [ "7670a421-f7a4-416c-a768-f678ced55be7" ], "related_substance": { "uuid": "347d4b9b-9f50-4022-9cbf-baa6412a35d7", "refuuid": "0378b911-1904-4bd9-bce7-87375b8c30ad", "name": "CL-4AS-1", "unii": "24SF5976Y2", "linking_id": "24SF5976Y2", "ref_pname": "CL-4AS-1" } }, { "uuid": "fcbcd7d1-759f-49ea-9212-1ff607d3c443", "amount": { "uuid": "dd9f6c3f-2cad-4d92-bc32-ae5373c9b939" }, "type": "INHIBITOR->TARGET", "interaction_type": "IN-VIVO", "references": [ "d930739b-939b-4048-99df-0eea1aab1a02" ], "related_substance": { "uuid": "cb88c96f-14f7-43d7-a9d6-5d7c19a42df7", "refuuid": "800a6b46-ef91-408f-bc9a-e2dcdb9b9438", "name": "RU-56279", "unii": "6PAG4TC385", "linking_id": "6PAG4TC385", "ref_pname": "RU-56279" } }, { "uuid": "d097cdb4-2938-401b-8453-1dcfbd96e3ba", "amount": { "uuid": "0531a260-ec55-4fde-95b9-bdc3364420e9" }, "type": "AGONIST->TARGET", "references": [ "89ed3db0-c479-4e17-8dd2-623893093439" ], "related_substance": { "uuid": "16959ef3-b793-4b65-b90d-e660ebee9a60", "refuuid": "76f67d1e-a498-49fc-ba1b-01221ba4b4c0", "name": "GSK-2849446", "unii": "G6UPC5EU71", "linking_id": "G6UPC5EU71", "ref_pname": "GSK-2849446", "substance_class": "reference" } }, { "uuid": "c8dc34db-b49f-4868-b586-05093ee820ef", "amount": { "uuid": "0c4916c4-5e78-46bf-9a98-a92f5854c7c3" }, "type": "AGONIST->TARGET", "related_substance": { "uuid": "12a4e9c8-a68c-4a4f-8ac2-cceeb6721fb8", "refuuid": "90ef50cb-a067-4f9e-ba33-54e335ea6fd2", "name": "VOSILASARM", "unii": "4O87Q44KNC", "linking_id": "4O87Q44KNC", "ref_pname": "VOSILASARM", "substance_class": "reference" } }, { "uuid": "6994e3f2-1f77-4fe8-aeae-94f51a3a685c", "amount": { "uuid": "8ae41e96-ac65-4624-b8eb-ccf61999b236" }, "type": "AGONIST->TARGET", "related_substance": { "uuid": "4b308a75-8080-4989-9d00-3af2df4faab2", "refuuid": "dab24b6e-d8e2-423d-ae5c-d53136f4e5d7", "name": "LGD-2941", "unii": "27H8PR7JGK", "linking_id": "27H8PR7JGK", "ref_pname": "LGD-2941", "substance_class": "reference" } }, { "uuid": "f23c5d47-c8bc-466d-9a51-44e626236c9f", "amount": { "uuid": "95af495f-3373-47e7-811f-a0c7af4ea8bf" }, "type": "AGONIST->TARGET", "references": [ "43afb71b-9b78-49d2-adf3-e764566d0519" ], "related_substance": { "uuid": "e835d454-de6a-4dc6-becb-3218add107bd", "refuuid": "e88372af-8c18-4033-b5fe-4febfb802bff", "name": "TRESTOLONE", "unii": "40P3287I94", "linking_id": "40P3287I94", "ref_pname": "TRESTOLONE" } }, { "uuid": "3f7bf484-9ca9-4d41-8416-26b720a93703", "amount": { "uuid": "a10b8bf8-3a19-4c6d-aa7e-9c47e23909cc" }, "type": "AGONIST->TARGET", "references": [ "f05b76ee-23fa-4248-80f4-f4e7fc387f53", "35f267c5-ff00-46f8-8bff-168fecbe1bd6" ], "related_substance": { "uuid": "03f5a6cb-1854-4e47-a07b-4431cb5a2257", "refuuid": "7f3b6784-5a3c-4bfa-9611-14280386f51a", "name": "1-TESTOSTERONE", "unii": "Y984BV1Q0G", "linking_id": "Y984BV1Q0G", "ref_pname": "1-TESTOSTERONE" } }, { "uuid": "fea8a655-b43f-41dd-89dd-51f17000c4df", "amount": { "uuid": "9ea8a2bf-8cfc-41bb-ad49-5b1bd8272c8f" }, "type": "INHIBITOR->TARGET", "references": [ "4f5b450b-3e85-46e9-9e8f-b58e4b465080" ], "related_substance": { "uuid": "d41c68d1-ee82-4480-9d8d-317180d7b146", "refuuid": "8cd53fb9-a453-4cca-aa0d-0b6337bfa164", "name": "PRUXELUTAMIDE", "unii": "QX6O64GP40", "linking_id": "QX6O64GP40", "ref_pname": "PRUXELUTAMIDE", "substance_class": "reference" } }, { "uuid": "a14c0c75-ae1c-4d74-a3f8-1455b4c0ee05", "amount": { "uuid": "2e90c340-4f67-4cec-bc56-ccc5ccdb4739" }, "type": "INHIBITOR->TARGET", "references": [ "2e36cd1e-9426-4354-af12-4f8a09e0b44b" ], "related_substance": { "uuid": "5406ea83-7a2c-4618-a917-56cbdb0bc6f1", "refuuid": "1067654e-0f2f-4519-8e21-688ce6c6427b", "name": "RALANITEN", "unii": "WC830G6O4X", "linking_id": "WC830G6O4X", "ref_pname": "RALANITEN", "substance_class": "reference" } }, { "uuid": "8494293c-8bc5-45de-9f0f-9e7d3993262d", "amount": { "uuid": "a62a6f65-0159-4b1a-85ba-e871c32f91d3" }, "type": "AGONIST->TARGET", "references": [ "e6f90340-65b8-4e5e-9ecb-188c6cc89fef" ], "related_substance": { "uuid": "1bf1af87-b4ab-4193-8f62-4f1087c9385c", "refuuid": "3a51e889-67df-46d0-9fe6-31eafd1e3693", "name": "MK-0773", "unii": "5730VNW22X", "linking_id": "5730VNW22X", "ref_pname": "MK-0773", "substance_class": "reference" } }, { "uuid": "7168d93a-487c-490a-a509-2b6ae5db4a59", "amount": { "uuid": "e966ded8-1d3d-4090-af62-ad2fa6a806eb" }, "comments": "ARD-69 is a potent proteolysis-targeting chimera (PROTAC) degrader of the androgen receptor (AR) that was designed as a proof-of-concept lead to evaluate the potential of PROTAC technology as a novel treatment mechanism for AR-positive, castration-resistant prostate cancer [2]. It contains an AR antagonist (reported in [1]) that binds the AR, joined by a small linker molecule to a second ligand (in this case a VHL ligand) that engages the E3 ubiquitin ligase system via Cullin-2. This chimeric molecular structure targets AR protein for ubiquitination-dependent proteolysis.", "type": "DEGRADER, SELECTIVE->TARGET", "references": [ "76873134-3dd6-42d0-a08d-6a9313de2ac3" ], "related_substance": { "uuid": "12d3aebe-0f5f-4643-bb94-c2b9fc6b09c4", "refuuid": "913a5b1f-e829-44ab-9b3c-ba55e81ec401", "name": "ARD-69", "unii": "6V4BB6JQ6C", "linking_id": "6V4BB6JQ6C", "ref_pname": "ARD-69", "substance_class": "reference" } }, { "uuid": "855c78ab-5083-4459-8f7a-f198b5770fba", "amount": { "uuid": "33ba29cc-f088-4a4a-b8c0-474cf279b7a4", "average": 0.8, "units": "NANOMOLAR" }, "qualification": "Kd", "type": "RADIOLIGAND->TARGET", "references": [ "8f29ac37-08f0-4f97-aeb7-d1a373c93501" ], "related_substance": { "uuid": "28cd1ea6-d49a-436d-b68f-8146969cd1a5", "refuuid": "525dcf4b-4c61-45af-a15e-abdae4fefc44", "name": "Methyltrienolone H-3", "unii": "A4TL3XLM32", "linking_id": "A4TL3XLM32", "ref_pname": "Methyltrienolone H-3", "substance_class": "reference" } }, { "uuid": "8df89d07-f003-484b-a500-bd3a875393fb", "amount": { "uuid": "781acb93-e8cb-43a6-80c4-910aa995c4fc", "average": 25000, "units": "NANOMOLAR" }, "qualification": "EC50", "type": "AGONIST->TARGET", "references": [ "c99be1dc-b781-4097-b0da-855925e70277" ], "related_substance": { "uuid": "07d2c417-113f-4639-9b48-3e41a39eff09", "refuuid": "886f9b9f-def0-4860-b322-fba057aaf03a", "name": "5.ALPHA.-HYDROXY LAXOGENIN", "unii": "844KE20WT5", "linking_id": "844KE20WT5", "ref_pname": "5.ALPHA.-HYDROXY LAXOGENIN", "substance_class": "reference" } }, { "uuid": "76881ee8-9599-45d2-a0f1-8d0194e495ad", "amount": { "uuid": "2ed20c03-4c52-4782-95e8-517094682347", "average": 5.8, "units": "NANOMOLAR" }, "qualification": "IC50", "type": "AGONIST->TARGET", "interaction_type": "BINDING", "references": [ "d4f64027-8331-4453-8137-c35ec2a9da79" ], "related_substance": { "uuid": "0ed49402-6bba-437f-98c6-8482c043b082", "refuuid": "7545274c-75cc-47ff-b51b-387c92d4e188", "name": "Progesterone", "unii": "4G7DS2Q64Y", "linking_id": "4G7DS2Q64Y", "ref_pname": "Progesterone", "substance_class": "reference" } }, { "uuid": "13f94b2b-1b2c-4526-9594-e1ef0bb8be3c", "amount": { "uuid": "59ce4aee-e76d-4d0e-8f5a-5ef016d20863" }, "type": "RADIOLIGAND->TARGET", "references": [ "3a21725e-bd3d-47b6-910b-0f11e893d3cb" ], "related_substance": { "uuid": "34196ece-332d-4382-a307-59eaf50edeb4", "refuuid": "566aa318-0649-4923-a153-7e25fd995762", "name": "16.BETA.-FLUORODIHYDROTESTOSTERONE F-18", "unii": "1833833586", "linking_id": "1833833586", "ref_pname": "16.BETA.-FLUORODIHYDROTESTOSTERONE F-18", "substance_class": "reference" } }, { "uuid": "72c0e742-9891-4839-8cf8-d6825ce137b8", "amount": { "uuid": "c364e4b3-8855-44fb-9a0e-941c812d08f7", "average": 0.1, "units": "NANOMOLAR" }, "comments": "In VCaP cells", "qualification": "DC50", "type": "DEGRADER, SELECTIVE->TARGET", "related_substance": { "uuid": "9f9cea1e-c7fe-45d7-80ea-c85bb2fb01a2", "refuuid": "929ca595-6bc9-448c-acee-a749556e620c", "name": "ARD-1676", "unii": "PAK8EC5GPR", "linking_id": "PAK8EC5GPR", "ref_pname": "ARD-1676", "substance_class": "reference" } }, { "uuid": "9623bbbc-3b43-4a76-b287-b3f82883373b", "amount": { "uuid": "eac9f3d7-4081-43f6-a146-8f7f1a71123c" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "aaaf6178-37a3-4276-bbb5-fe4e8189a2b9", "refuuid": "93fe5236-2708-41be-bc06-af6ce3ba6ef8", "name": "TOPILUTAMIDE", "unii": "A8EU2FXY13", "linking_id": "A8EU2FXY13", "ref_pname": "TOPILUTAMIDE", "substance_class": "reference" } }, { "uuid": "05d3cc62-ceb2-478d-8823-df5f7ae09aa3", "amount": { "uuid": "309248f3-07f8-40a2-94f4-09077ec1f761", "average": 5.76, "high": 9.28, "low": 2.18, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "interaction_type": "BINDING", "related_substance": { "uuid": "de4e1ef4-ace5-4627-b21c-ba542664ce0b", "refuuid": "7d867a7b-3209-4d6e-bfd1-ef67ce2175f9", "name": "NOMEGESTROL ACETATE", "unii": "83J78V5W05", "linking_id": "83J78V5W05", "ref_pname": "NOMEGESTROL ACETATE", "substance_class": "reference" } }, { "uuid": "11eb7f6e-4c53-4626-a111-4a4a5ff54a07", "amount": { "uuid": "6ff69059-9ff3-4d7a-add5-8aaf297d6969", "average": 5.4, "units": "NANOMOLAR" }, "qualification": "IC50", "type": "INHIBITOR->TARGET", "interaction_type": "BINDING", "references": [ "68a64a85-b8b8-4c5f-a74a-d9dc2347d2bd" ], "related_substance": { "uuid": "52af052f-1fe7-4ab8-b148-0077917fdc9a", "refuuid": "de5088e3-60d2-48db-8c91-311bd3435f32", "name": "TESTOSTERONE", "unii": "3XMK78S47O", "linking_id": "3XMK78S47O", "ref_pname": "TESTOSTERONE", "substance_class": "reference" } }, { "uuid": "a66d35d7-7917-4009-acce-1bc74d315d22", "amount": { "uuid": "8139ba2e-b050-4650-9cfa-23ec4f46c1ba", "average": 21, "units": "NANOMOLAR" }, "qualification": "IC50", "type": "AGONIST->TARGET", "interaction_type": "BINDING", "references": [ "2fdc4026-fc90-419e-bb4d-4e978916af3e" ], "related_substance": { "uuid": "4fa730a3-7f85-463f-9a2f-37c5c6b1ca9a", "refuuid": "dbe30db9-e2f7-42a1-897d-344c3d8f9272", "name": "ESTRADIOL", "unii": "4TI98Z838E", "linking_id": "4TI98Z838E", "ref_pname": "ESTRADIOL", "substance_class": "reference" } }, { "uuid": "5984d0db-d45a-41cb-9ac1-73b35ed5b77b", "amount": { "uuid": "adee92c3-5f43-419e-b205-8399f89248cf" }, "type": "AGONIST->TARGET", "references": [ "ac76683f-2dd2-4266-8b9c-06f991d804a3" ], "related_substance": { "uuid": "b5b9a4d5-1c68-436f-b3d4-07e14bed2e16", "refuuid": "c9acd34f-2ced-428a-97f8-57333e956b21", "name": "Testosterone glucoside", "unii": "558BM62QQ3", "linking_id": "558BM62QQ3", "ref_pname": "Testosterone glucoside", "substance_class": "reference" } }, { "uuid": "6bde2410-a34b-4b1c-a5e2-fe2c49dac74d", "amount": { "uuid": "203cb5a4-73f5-46b0-a05f-4428fc2a3d3d", "average": 47, "units": "NANOMOLAR" }, "qualification": "Ki", "type": "INHIBITOR->TARGET", "references": [ "1b38fa3e-1f9c-4cea-8eff-6779919abbe2" ], "related_substance": { "uuid": "88e8ebe6-3110-4233-8b7e-dcb59eeaf9c7", "refuuid": "57b535c2-ea60-4a8c-825a-bf7755acb7b4", "name": "ODM-204", "unii": "MUA9S35FLZ", "linking_id": "MUA9S35FLZ", "ref_pname": "ODM-204", "substance_class": "reference" } } ], "names": [ { "uuid": "dee17cdc-b4b5-4a77-bdbc-c7602b04e4b0", "name": "ANDROGEN RECEPTOR", "stdName": "ANDROGEN RECEPTOR", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "1aebf022-acfd-43df-b384-e318fd3bad2c", "11b93b91-8b76-4c13-bae4-f13ddccd22d7" ], "display_name": true }, { "uuid": "3f7e4e20-6d50-459a-8bcd-65b7fd500237", "name": "AR", "stdName": "AR", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "1aebf022-acfd-43df-b384-e318fd3bad2c", "11b93b91-8b76-4c13-bae4-f13ddccd22d7" ], "display_name": false }, { "uuid": "683f9a52-e919-4d1a-af9f-4089e4403fdc", "name": "DHTR", "stdName": "DHTR", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "1aebf022-acfd-43df-b384-e318fd3bad2c", "11b93b91-8b76-4c13-bae4-f13ddccd22d7" ], "display_name": false }, { "uuid": "f3645a7a-46b9-4193-8025-4a79a2f30883", "name": "DIHYDROTESTOSTERONE RECEPTOR", "stdName": "DIHYDROTESTOSTERONE RECEPTOR", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "1aebf022-acfd-43df-b384-e318fd3bad2c", "11b93b91-8b76-4c13-bae4-f13ddccd22d7" ], "display_name": false }, { "uuid": "dd046333-6f16-450e-92e6-0480323fbcb6", "name": "NR3C4", "stdName": "NR3C4", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "1aebf022-acfd-43df-b384-e318fd3bad2c", "11b93b91-8b76-4c13-bae4-f13ddccd22d7" ], "display_name": false }, { "uuid": "f34b68fc-6520-4f28-89ea-543c2bcfb7e6", "name": "NUCLEAR RECEPTOR SUBFAMILY 3 GROUP C MEMBER 4", "stdName": "NUCLEAR RECEPTOR SUBFAMILY 3 GROUP C MEMBER 4", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "1aebf022-acfd-43df-b384-e318fd3bad2c", "11b93b91-8b76-4c13-bae4-f13ddccd22d7" ], "display_name": false } ], "protein": { "uuid": "b760f7a2-8558-4742-9f12-4469c65a95c1", "glycosylation": { "uuid": "dafe77b4-931a-4295-bac4-31593805b11c" }, "subunits": [ { "uuid": "aa35b783-898f-4f93-887a-d085676ef3ff", "sequence": "MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGLEGESLGCSGSAAAGSSGTLELPSTLSLYKSGALDEAAAYQSRDYYNFPLALAGPPPPPPPPHPHARIKLENPLDYGSAWAAAAAQCRYGDLASLHGAGAAGPGSGSPSAAASSSWHTLFTAEEGQLYGPCGGGGGGGGGGGGGGGGGGGGGGGEAGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGPWMDSYSGPYGDMRLETARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGEASSTTSPTEETTQKLTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ", "subunit_index": 1 } ], "references": [ "1aebf022-acfd-43df-b384-e318fd3bad2c", "ce16afd0-9fa7-49fc-aacc-6f0eed1c4e51" ], "other_links": [ { "uuid": "dc419cba-ff32-43dd-aa6b-6acf3a36a7be", "sites": [ { "residue_index": 560, "subunit_index": 1 }, { "residue_index": 563, "subunit_index": 1 }, { "residue_index": 577, "subunit_index": 1 }, { "residue_index": 580, "subunit_index": 1 } ], "linkage_type": "COORDINATION COMPOUND" }, { "uuid": "64c2fdda-2911-4708-88ae-5445096abe31", "sites": [ { "residue_index": 596, "subunit_index": 1 }, { "residue_index": 602, "subunit_index": 1 }, { "residue_index": 612, "subunit_index": 1 }, { "residue_index": 615, "subunit_index": 1 } ], "linkage_type": "COORDINATION COMPOUND" } ], "protein_sub_type": "", "sequence_type": "COMPLETE" }, "properties": [ { "uuid": "a7d2c48c-174c-4ce1-b4f1-cd09ac95ec48", "name": "MOL_WEIGHT", "type": "amount", "value": { "uuid": "b81aeea2-ffb9-470a-a2b4-5cd50fc3af0a", "units": "DA" }, "defining": false, "property_type": "CHEMICAL" }, { "uuid": "ed761a4e-0c29-4104-88fe-c78e19899884", "name": "Molecular Formula", "value": { "uuid": "25165e21-b517-43eb-8735-63d22162fe2a", "type": "ESTIMATED", "non_numeric_value": "C4342H6752N1220O1347S49" }, "defining": false, "property_type": "CHEMICAL" } ], "modifications": { "uuid": "8743ec42-4db3-46bb-b23f-7dff91b7dd3d", "structural_modifications": [ { "uuid": "7812bdd9-5337-4a9e-8d0d-5b09af6a64a1", "sites": [ { "residue_index": 560, "subunit_index": 1 }, { "residue_index": 563, "subunit_index": 1 }, { "residue_index": 577, "subunit_index": 1 }, { "residue_index": 580, "subunit_index": 1 } ], "location_type": "SITE_SPECIFIC", "molecular_fragment": { "uuid": "2f85a33b-09cd-4774-9844-8493d3514910", "refuuid": "82bdb684-c993-4600-aae0-0ff45a663b9f", "name": "C4-TYPE ZINC FINGER", "unii": "C56TF4V7OP", "linking_id": "C56TF4V7OP", "ref_pname": "C4-TYPE ZINC FINGER", "substance_class": "reference" }, "structural_modification_type": "AMINO_ACID_SUBSTITUTION" }, { "uuid": "97590237-6682-4b61-82a3-82562e30cba8", "sites": [ { "residue_index": 596, "subunit_index": 1 }, { "residue_index": 602, "subunit_index": 1 }, { "residue_index": 612, "subunit_index": 1 }, { "residue_index": 615, "subunit_index": 1 } ], "location_type": "SITE_SPECIFIC", "molecular_fragment": { "uuid": "4966a2ec-94b9-4e15-a90d-e15bd6c662e5", "refuuid": "82bdb684-c993-4600-aae0-0ff45a663b9f", "name": "C4-TYPE ZINC FINGER", "unii": "C56TF4V7OP", "linking_id": "C56TF4V7OP", "ref_pname": "C4-TYPE ZINC FINGER", "substance_class": "reference" }, "structural_modification_type": "AMINO_ACID_SUBSTITUTION" } ] } } ] }